With sales of $103 million in the fourth quarter and $180 million in its first nine months on the market, Madrigal ...

BofA raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $239 from $154 and keeps an Underperform rating on the shares. The Q4 ...

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain ...

H.C. Wainwright raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $405 from $400 and keeps a Buy rating on the shares ...

Madrigal Pharmaceuticals MDGL reported fourth-quarter 2024 loss of $2.71 per share, narrower than the Zacks Consensus ...

Benzinga's options scanner spotted 9 options trades for Madrigal Pharmaceuticals. This is not a typical pattern. The sentiment among these major traders is split, with 44% bullish and 44% bearish.

But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. So, the natural question for Madrigal Pharmaceuticals (NASDAQ:MDGL) shareholders is whether ...

The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...

Investors have grown concerned about the sector amid reports — which became reality — that President Trump would tap Robert F ...

Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales ...

Welcome to Madrigal Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call. (Operator Instructions) As a reminder, today's conference call is being recorded. I'd like to introduce Ms. Tina ...